Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)

426 cGMP production of a chimeric virus-like particle vaccine (RG1-VLP) for prevention of HPV-associated cancers

(2016) R. Kirnbauer et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles

(2016) Mathieu Boxus et al.   JOURNAL OF VIROLOGY

Human papillomavirus detected in viral warts of renal transplant recipients

(2016) F. Martelli-Marzagão et al.   Transplant Infectious Disease

A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects

(2016) Erin M. Scherer et al.   EBioMedicine

Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2

(2015) Ebenezer Tumban et al.   VACCINE

Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach

(2015) Wai-Hong Wu et al.   Virology Journal

Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia

(2015) Nagayasu Egawa et al.   Viruses-Basel

HPV Carcinomas in Immunocompromised Patients

(2015) Nicole Reusser et al.   Journal of Clinical Medicine

A Chimeric 18L1-45RG1 Virus-Like Particle Vaccine Cross-Protects against Oncogenic Alpha-7 Human Papillomavirus Types

(2015) Bettina Huber et al.   PLoS One

Betapapillomaviruses in the anal canal of HIV positive and HIV negative men who have sex with men

(2014) Boštjan Mlakar et al.   JOURNAL OF CLINICAL VIROLOGY

HumanBeta-papillomavirusinfection and keratinocyte carcinomas

(2014) Koen D Quint et al.   JOURNAL OF PATHOLOGY

A Cryo-Electron Microscopy Study Identifies the Complete H16.V5 Epitope and Reveals Global Conformational Changes Initiated by Binding of the Neutralizing Antibody Fragment

(2014) Hyunwook Lee et al.   JOURNAL OF VIROLOGY

Impact of Inhibitors and L2 Antibodies upon the Infectivity of Diverse Alpha and Beta Human Papillomavirus Types

(2014) Kihyuck Kwak et al.   PLoS One

Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes

(2014) Kirill Kalnin et al.   VACCINE

Comparison of the immunogenicity of Cervarix®and Gardasil®human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults

(2014) Lars Toft et al.   Human Vaccines & Immunotherapeutics

Protective Vaccination against Papillomavirus-Induced Skin Tumors under Immunocompetent and Immunosuppressive Conditions: A Preclinical Study Using a Natural Outbred Animal Model

(2014) Sabrina E. Vinzón et al.   PLoS Pathogens

Immunogenicity of Quadrivalent Human Papillomavirus Vaccine in Organ Transplant Recipients

(2013) D. Kumar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses

(2013) Christina Schellenbacher et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Optimization of Multimeric Human Papillomavirus L2 Vaccines

(2013) Subhashini Jagu et al.   PLoS One

Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study

(2013) Lynette Denny et al.   VACCINE

A universal virus-like particle-based vaccine for human papillomavirus: Longevity of protection and role of endogenous and exogenous adjuvants

(2013) Ebenezer Tumban et al.   VACCINE

A Human Papillomavirus (HPV)In VitroNeutralization Assay That Recapitulates theIn VitroProcess of Infection Provides a Sensitive Measure of HPV L2 Infection-Inhibiting Antibodies

(2012) Patricia M. Day et al.   Clinical and Vaccine Immunology

Intranasal Vaccination with AAV5 and 9 Vectors Against Human Papillomavirus Type 16 in Rhesus Macaques

(2012) Karen Nieto et al.   HUMAN GENE THERAPY

Warts and all: Human papillomavirus in primary immunodeficiencies

(2012) Jennifer W. Leiding et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice

(2012) Sun-Woo Yoon et al.   VACCINE

The Oral Cavity Contains Abundant Known and Novel Human Papillomaviruses From the Betapapillomavirus and Gammapapillomavirus Genera

(2011) Danielle Bottalico et al.   JOURNAL OF INFECTIOUS DISEASES

A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2

(2011) Ebenezer Tumban et al.   PLoS One

The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic

(2011) Shahan Mamoor et al.   VIROLOGY

Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens inCervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine

(2010) Michel Deschuyteneer et al.   Human vaccines & immunotherapeutics

Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old

(2010) Myron J Levin et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection

(2010) Subhashini Jagu et al.   VACCINE

Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments

(2010) Hans-Ulrich Bernard et al.   VIROLOGY

Presence of beta human papillomaviruses in nonmelanoma skin cancer from organ transplant recipients and immunocompetent patients in the West of Scotland

(2009) L.J. Mackintosh et al.   BRITISH JOURNAL OF DERMATOLOGY

Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines

(2009) Subhashini Jagu et al.   JNCI-Journal of the National Cancer Institute

Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines

(2009) C. Schellenbacher et al.   JOURNAL OF VIROLOGY

The EVER Proteins as a Natural Barrier against Papillomaviruses: a New Insight into the Pathogenesis of Human Papillomavirus Infections

(2009) M. Lazarczyk et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20–38) peptide displayed on bacterial thioredoxin

(2009) Ivonne Rubio et al.   VACCINE

Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs

(2009) Tilo Senger et al.   VACCINE

Dermatologic manifestations of HPV in HIV-infected individuals

(2009) Rachel H. Gormley et al.   Current HIV/AIDS Reports

Serological relationship between cutaneous human papillomavirus types 5, 8 and 92

(2008) A. Handisurya et al.   JOURNAL OF GENERAL VIROLOGY

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2

(2008) H. H. Alphs et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA